EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the secondline treatment of advanced non-small cell lung cancer (NSCLC)

  • Shim, B. Y.
  • Lee, S.
  • de Castro Carpeno, J.
  • Chiu, C-H.
  • Cobo, M.
  • ... Ryu, J. S.
  • 외 7명
Citations

WEB OF SCIENCE

6
제목
EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the secondline treatment of advanced non-small cell lung cancer (NSCLC)
저자
Shim, B. Y.Lee, S.de Castro Carpeno, J.Chiu, C-H.Cobo, M.Kim, H. R.Ryu, J. S.Tarruella, M. M.Summers, Y.Thomas, C. A.Xu, Y.Lowy, I.Rietschel, P.
DOI
10.1016/j.annonc.2020.08.1583
발행일
2020-09
유형
Meeting Abstract
저널명
Annals of Oncology
31
페이지
S820 ~ S820